Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

NCT01828476 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped The Investigator left the organization.

Conditions

Prostate Cancer

Interventions

DRUG: Abiraterone
DRUG: ABT-263
DRUG: Hydroxychloroquine

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]
[object Object]
[object Object]